Firm News

Wiggin and Dana represented its client Rallybio Corporation (Rallybio), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders, in its license of worldwide exclusive rights to Sanofi’s KY1066 (RLYB331 going forward), a preclinical potentially first-in-class antibody with the potential to address a significant unmet need for patients with severe anemia with ineffective erythropoiesis and iron overload. Under the terms of the license agreement, Partner Patti Melick and Associate Kelsey Loomis are proud and grateful to have had the opportunity to contribute to the success of this transaction.

To read the official press release, please click here.